A review of sex-specific benefits and risks of antithrombotic therapy in acute coronary syndrome.
Over the past decade, more men than women have shown improved outcomes from antithrombotic therapies after acute coronary syndrome (ACS), which raises the question of whether there are sex-specific differences in treatment patterns and response to therapy. Differences in presenting clinical characteristics, pathophysiologic profile, and disparities in treatment may contribute to this outcomes discrepancy. Analyses of large trials and registry data suggest that male and female ACS patients experience similar benefits from antithrombotic therapy without significant difference in treatment utilization rates, yet women are consistently at higher risk of bleeding than men. Bleeding may result in antithrombotic treatment disruption, which increases the risk of long-term thrombotic events. Additionally, female ACS patients are more likely to receive suboptimal medication dosing and have lower rates of long-term medication adherence. These differences have significant clinical implications for women, indicating the need for strategies that will optimize initial treatment and long-term management attuned to these recognized sex-specific gaps.
Duke Clinical Research Institute, Duke University Medical Center, Duke Box 3850, 2400 Pratt Street, Durham, NC, USA.
William T
WT
Wang
Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.
Stefan K
SK
James
Duke Clinical Research Institute, Duke University Medical Center, Duke Box 3850, 2400 Pratt Street, Durham, NC, USA.
Tracy Y
TY
Wang
D054058:Acute Coronary Syndrome / Q000188:drug therapy*; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D005544:Forecasting; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D008297:Male; D012307:Risk Factors; D012727:Sex Characteristics; D016896:Treatment Outcome
D005343:Fibrinolytic Agents
Acute coronary syndrome; Antithrombotic therapy; Sex-specific differences